AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7029294
Drug: 3 drugs
RxNorm normalized name: goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 drugs and bilateral pulmonary irradiation (approximately 1,500 rad in 2 weeks)
Trial: 7029294
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) doses to the primary tumor
Trial: 30939480
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment group (systolic blood pressure target of < 120 mm Hg)
Trial: 30939480
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment group (systolic blood pressure target of < 140 mm Hg)
Trial: 25919263
Drug: Active pulsed
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active pulsed electromagnetic field therapy
Trial: 25919263
Drug: Sham pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham pulsed electromagnetic field therapy
Trial: 21851939
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg on cycle days 3-7)
Trial: 21851939
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (50 mg on cycle days 5-9)
Trial: 7641905
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (CE) alone (0.625 mg daily)
Trial: 7641905
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (CE) plus medrogestone (5 mg during the last 12 days of each 28-day cycle)
Trial: 2653402
Drug: colchicine 0.5
RxNorm normalized name: colchicine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: colchicine 0.5 mg bd for 1 week
Trial: 943169
Drug: Urea-lactic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea-lactic acid ointment
Trial: 16499489
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of long-acting naltrexone 380 mg
Trial: 16499489
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of long-acting naltrexone 380 mg every 28 days for a total of 4 doses
Trial: 16499489
Drug: Oral naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral naltrexone 50 mg daily for 5 days followed by IM long-acting naltrexone 380 mg
Trial: 16499489
Drug: Oral naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral naltrexone 50 mg
Trial: 11360489
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nifedipine administered sublingually with a hole in it
Trial: 11360489
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nifedipine administered intranasally with a syringe
Trial: 11360489
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nifedipine administered orally (contents administered orally)
Trial: 11360489
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nifedipine (capsule bitten and swallowed)
Trial: 29931216
Drug: Romosozumab 210
RxNorm normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romosozumab 210 mg subcutaneously monthly for 12 months
Trial: 16200586
Drug: Clofazimine (CFZ)
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofazimine (CFZ) at 100 mg/day
Trial: 16200586
Drug: Chloroquine diphosphate
RxNorm normalized name: CHLOROQUINE DIPHOSPHATE, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine diphosphate (CDP) at 250 mg/day
Trial: 10895850
Drug: Repaglinide/troglitazone combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide/troglitazone combination therapy
Trial: 10895850
Drug: Troglitazone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone monotherapy
Trial: 8795325
Drug: Injection pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection pressure of 250 g.cm‐2 (group 2)
Trial: 8795325
Drug: Injection pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection pressure of 140 g.cm‐2 (group 1)
Trial: 1354566
Drug: terfenadine 120
RxNorm normalized name: terfenadine 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine 120 mg (Triludan Forte)
Trial: 1354566
Drug: cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cetirizine 10 mg (Zirtek)
Trial: 28937862
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral carbohydrate (Nutricia Preop; n = 45)
Trial: 16111583
Drug: Moderate rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate rectal radiation doses
Trial: 12825239
Drug: Sulpiride (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (50 mg, three times per day for three months)
Trial: 12825239
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered three times per day for three months)
Trial: 1900383
Drug: Diet M
RxNorm normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet M (70 g sunflower margarine, P:S 1.1)
Trial: 1900383
Drug: Diet B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet B (70 g butter, P:S 0.2)
Trial: 6860528
Drug: Diclofensine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofensine 25 mg and 50 mg
Trial: 31735591
Drug: 10% povidone
RxNorm normalized name: POVIDONE-IODINE 100 mg in 1 mL TOPICAL LIQUID [Saninta 10% Povidone-Iodine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% povidone iodine preparation (single application)
Trial: 31735591
Drug: Twice-daily treatment
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily treatment for 5 days with 10% povidone iodine
Trial: 31285147
Drug: Opicinumab 3
RxNorm normalized name: Opicinumab
DrugBank: Opicinumab (DB14959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicinumab 3 mg/kg
Trial: 31285147
Drug: Opicinumab 10
RxNorm normalized name: Opicinumab
DrugBank: Opicinumab (DB14959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicinumab 10 mg/kg
Trial: 31285147
Drug: Opicinumab 30
RxNorm normalized name: Opicinumab
DrugBank: Opicinumab (DB14959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicinumab 30 mg/kg
Trial: 31285147
Drug: Opicinumab 100
RxNorm normalized name: Opicinumab
DrugBank: Opicinumab (DB14959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicinumab 100 mg/kg
Trial: 24914426
Drug: Cervitec Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervitec Plus (1% chlorhexidine‐1% thymol varnish) + Cervitec Gel (0.2% chlorhexidine‐0.2% sodium fluoride)
Trial: 22076422
Drug: Atorvastatin 80mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80mg, ezetimibe 10mg (Group A)
Trial: 11128860
Drug: 38 mg
RxNorm normalized name: alloin 38 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38 mg x kg(‐1) x d(‐1)
Trial: 11128860
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg x kg(‐1) x d(‐1)
Trial: 11128860
Drug: 76 mg
RxNorm normalized name: menthol 76 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 76 mg x kg(‐1) x d(‐1)
Trial: 9191523
Drug: Recombinant interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant interferon-alpha (IFN-alpha) at a dose of 3 MU given intramuscularly 3 times a week for 6 months with a 1-month interval between cycles.
Trial: 1554195
Drug: ICI 204219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 204219 (20 mg)
Trial: 3927279
Drug: Metoclopramide (dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (dopamine receptor blocker)
Trial: 20585108
Drug: KNO3 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KNO3 capsules (4 mmol, 12 mmol, or 24 mmol)
Trial: 20585108
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (250 mL, 5.5 mmol nitrate)
Trial: 18568474
Drug: Ice-cream containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice-cream containing Bifidobacterium lactis Bb-12
Trial: 18568474
Drug: Control ice-cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control ice-cream without viable bacteria
Trial: 16353677
Drug: Hair removal
RxNorm normalized name: Kendra SKIN PROTECTION and PAIN RELIEF FOR HAIR REMOVAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hair removal by clipper or depilatory cream
Trial: 12050273
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (24 mg/ml)
Trial: 8721040
Drug: Strawberry flavor
RxNorm normalized name: Strawberry Flavor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strawberry flavor of ondansetron syrup
Trial: 8721040
Drug: Grape flavor
RxNorm normalized name: Grape Flavor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape flavor of ondansetron syrup
Trial: 1757606
Drug: 0.05% halobetasol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% halobetasol propionate ointment
Trial: 795190
Drug: 0.1% diflucortolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% diflucortolone valerate ointment
Trial: 25512466
Drug: Allopurinol 500
RxNorm normalized name: allopurinol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 500 mg intravenous (ALLO)
Trial: 25512466
Drug: Placebo intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous (CONT)
Trial: 23074122
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) with propofol
Trial: 20802165
Drug: Written action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written action plan coupled with a prescription (WAP-P)
Trial: 20802165
Drug: Unformatted prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unformatted prescription (UP)
Trial: 18034777
Drug: Conivaptan 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conivaptan 40 mg/day
Trial: 18034777
Drug: Conivaptan 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conivaptan 80 mg/day
Trial: 10199774
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment at a mean dose of 1 UI/day for 1 year
Trial: 10199774
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment at a mean dose of 1 UI/day for 2 years
Trial: 8568547
Drug: Tobramycin 150
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin 150 or 300 mg administered intramuscularly (i.m.)
Trial: 8568547
Drug: Tobramycin 300
RxNorm normalized name: TOBRAMYCIN 300MG/5ML SOLN,INHL,KIT 56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin 300 mg administered intramuscularly (i.m.)
Trial: 2269380
Drug: Topical MC
RxNorm normalized name: MC-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical MC 903 ointment (50 micrograms/g) alone
Trial: 2269380
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of topical MC 903 with UVB radiation
Trial: 2269380
Drug: Control (Topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Topical MC 903 alone)
Trial: 2269380
Drug: Control (Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Combination with UVB)
Trial: 23700406
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin administration over an 8-week period
Trial: 20530042
Drug: 12-week supervised
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week supervised exercise intervention followed by 12 weeks of self-administered exercise
Trial: 16997602
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of a single 2 ml dose of hylan G-F 20 into the hip joint under fluoroscopic guidance.
Trial: 15598477
Drug: Galantamine 8
RxNorm normalized name: galantamine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 8 mg/d
Trial: 12860500
Drug: Galantamine 16
RxNorm normalized name: galantamine 16 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 16 mg/d
Trial: 12860497
Drug: Galantamine 24
RxNorm normalized name: galantamine 24 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 24 mg/d
Trial: 15598477
Drug: Galantamine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (all doses combined)
Trial: 11903737
Drug: L-regimen (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-regimen (30 mg lansoprazole u.i.d)
Trial: 11903737
Drug: LC-regimen (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC-regimen (30 mg lansoprazole u.i.d. with 200 mg cetraxate q.i.d)
Trial: 9215029
Drug: Continuous extradural
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous extradural infusion of ropivacaine 2 mg ml-1 at 4 ml h-1
Trial: 9215029
Drug: Continuous extradural
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous extradural infusion of ropivacaine 2 mg ml-1 at 6 ml h-1
Trial: 9215029
Drug: Continuous extradural
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous extradural infusion of ropivacaine 2 mg ml-1 at 8 ml h-1
Trial: 9215029
Drug: Continuous extradural
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous extradural infusion of ropivacaine 2 mg ml-1 at 10 ml h-1
Trial: 8356864
Drug: 2 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg.kg‐1 propofol
Trial: 25743733
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution (Control)
Trial: 29067578
Drug: Transanal low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transanal low rectal dissection
Trial: 29067578
Drug: Laparoscopic low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic low rectal dissection
Trial: 27532874
Drug: Weekly telephone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly telephone intervention for three months
Trial: 22838094
Drug: OTC BPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTC BPO 5.5% formulation with lipohydroxy acid and tretinoin cream 0.025%
Trial: 22838094
Drug: Prescription clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription clindamycin 1%-BPO 5% gel and tretinoin cream 0.025%
Trial: 20542783
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (conservative group)
Trial: 16225497
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg intravenous)
Trial: 12373416
Drug: Flesinoxan 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flesinoxan 0.5 mg
Trial: 12373416
Drug: Flesinoxan 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flesinoxan 1 mg
Trial: 10404500
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of ethanol (0.5 g.kg‐1)
Trial: 8524562
Drug: Community care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community care by glaucoma-trained optometrists with reviews on a six monthly basis
Trial: 2178961
Drug: Fenoterol 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol 1.6 mg
Trial: 6108129
Drug: Ketotifen (HC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (HC 20-511) 1 mg twice daily for 12 weeks
Trial: 6108129
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) 20 mg four times daily for 12 weeks
Trial: 23794382
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) 10 mg IV
Trial: 20517223
Drug: Cytoflavin, 425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin, 425 mg, 2 tablets twice a day during 25 days
Trial: 20517223
Drug: Aminalon, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminalon, 500 mg, 2 tablets 3 times a day during 25 days
Trial: 10817549
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg of rofecoxib once daily
Trial: 10817549
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of rofecoxib once daily
Trial: 10817549
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of diclofenac 3 times daily
Trial: 8803643
Drug: Captopril (C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (C 50 mg bid)
Trial: 8803643
Drug: Ticlopidine (T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (T 250 mg bid)
Trial: 1465278
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C + high-dose medroxyprogesterone acetate (MMPA)
Trial: 26833461
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of 125‐mg, 250‐mg, or 500‐mg AZM suppository
Trial: 26833461
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of AZM 500‐mg tablet
Trial: 25785316
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg bolus before intubation, followed by 2 mg/kg/h continuous infusion)
Trial: 25785316
Drug: Saline (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (same dosage as lidocaine)
Trial: 18377121
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy only (CPT-C)
Trial: 1908314
Drug: CC/hMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC/hMG
Trial: 30999929
Drug: Namilumab 80
RxNorm normalized name: Namilumab
DrugBank: Namilumab (DB13037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Namilumab 80 mg
Trial: 24930436
Drug: adapalene in
RxNorm normalized name: Product containing adapalene in cutaneous dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adapalene in combination with a moisturizer (heparinoid)
Trial: 19473997
Drug: HSV suppressive
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSV suppressive treatment (placebo-controlled)
Trial: 3602020
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg pirprofen twice daily
Trial: 31576959
Drug: NSD plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSD plus MTZ (400 mg) and AMX (500 mg) three times a day for 14 days
Trial: 29921143
Drug: Mantram repetition
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mantram repetition therapy
Trial: 27730819
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium nitrate treatment
Trial: 23147874
Drug: Pressure Volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure Volume Loop (PV-L) closure technique
Trial: 17975151
Drug: 12-peptide vaccine
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-peptide vaccine containing a mixture of 12 peptides from melanocytic differentiation proteins and cancer‐testis antigens
Trial: 17975151
Drug: 4-peptide vaccine
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-peptide vaccine with only melanocytic differentiation peptides
Trial: 14727004
Drug: Ketamine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.4 mg kg(‐1))
Trial: 14727004
Drug: Ketamine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.8 mg kg(‐1))
Trial: 8153291
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (AmBisome) 1-1.38 mg/kg/day for 21 days